reason report
partnership expand focu beyond solid tumor pt
bottom line zlab announc region strateg
collabor add first clinic stage bispecif t-cell
engag zlab pipelin greater china zlab acquir
right develop exclus commerci
bispecif mainland china hong kong taiwan macau
immedi support global clinic develop
on-going phase ii registr trial overal view deal
strateg expans zlab pipelin hematolog malign
demonstr promis clinic data date follicular
lymphoma fl diffus larg b-cell lymphoma dlbcl howev
landscap competit includ clinical-stag
program rhhbi nr op gmab nr data
program present american societi
hematolog analyz abstract recal
zlab china-bas global biopharmaceut compani target
area unmet medic need china global market
in-licens intern discoveri effort oncolog infecti diseas
autoimmun diseas zlab maintain broad pipelin asset in-
licens gsk op op op op
asset zejula optun ripretinib margetuximab well
omadacyclin infecti diseas addit zlab
earli stage in-hous effort repres potenti sourc
long-term upsid investor continu view compani
favor experienc manag team posit execut
strategi reiter op price target
acquisit add bispecif t-cell engag hematolog
space zlab expand pipelin term
agreement op cover geoffrey porg receiv
up-front addit regulatori sale mileston
respons manufactur suppli
region zlab contribut global develop cost
certain trial make payment base net sale zlab
provid webcast present join select multipl
cohort registr phase ii program includ dlbcl
mzl relaps refractori b-nhl
demonstr promis data dlbcl fl
date phase updat present includ total
patient includ dlbcl patient fl mcl mzl
nhl indic orr fl patient treat
orr dlbcl patient treat
coverag data date found
multipl dr tgr
year price history/av daili volume mil zlab
compani inform svb leerink llc research
revenu present million ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
bispecif program develop includ rhhbi
mosunetuzumab op plamotamab previous
gmab epcoritamab previous
previous compar data present link
well data present previous includ european hematolog
associ eha link notabl accord zlab none
program start develop china
accord offici record
differ treatment landscap b-cell lymphoma
china notabl car-t therapi approv china date
although zlab point variou program develop
addit manag highlight multipl innov therapi
b-cell malign yet approv china includ
polatuzumab vedotin polivi obinutuzumab gazyva
inhibitor copanlisib duvelisib patient therefor reli
combin rituximab chemotherapi r-chop
estim probability-unadjust market opportun
nhl china includ opportun dlbcl fl
remain nhl subtyp valuat assign probabl
success china result probability-
adjust sale peak uptak year increas
price target
mileston catalyst includ potenti optun china
approv trial waiver launch gbm submit
optun malign pleural mesothelioma mpm approv
submit ripretinib partner mp cover andrew
beren nda file advanc gastrointestin stromal tumor gist
initi ripretinib gist bridg trial china
enrol first chines patient margetuximab gastric cancer global studi
mahogani enrol first chines patient pivot phase
attack trial sulbactam-durlobactam ind submiss
two in-hous discoveri program global ip
rate zlab outperform zai lab china-bas global biopharmaceut compani
target area unmet medic need china global market in-licens
intern discoveri effort oncolog infecti diseas autoimmun diseas
view zlab well-posit benefit china rapidli grow emerg biopharma market
strong manag team extens experi in-depth knowledg
evolv drug develop commerci landscap china zlab broad
pipelin asset in-licens gsk
oncolog ripretinib oncolog oncolog omadacyclin infecti
diseas addit zlab earli stage in-hous effort focus
oncolog autoimmun diseas repres potenti sourc long-term upsid
price target zlab base blend dcf analysi revenu
multipl analysi assign valu probability-weight opportun zejula ovarian
cancer probabl success ovarian cancer probabl success
ovarian cancer probabl success tripl neg breast cancer probabl
success brca breast cancer probabl success assign valu probability-
weight opportun omadacyclin absssi acute-bacteri skin skin-structur
infect probabl success cabp commun acquir bacteri pneumonia
probabl success assign valu probability-weight opportun ripretinib
gastrointestin stromal tumor gist probabl success across set
assign valu probability-weight opportun optun tumor treat field
glioblastoma probabl success mesothelioma probabl success non-
small cell lung cancer nsclc probabl success nsclc brain metastas
probabl success platinum-resist ovarian cancer probabl success
pancreat cancer probabl success assign valu probability-weight
opportun non-hodgkin lymphoma nhl probabl success
assign valu probability-weight opportun gastric cancer probabl
success assign valu probability-weight opportun margetuximab
metastat breast cancer probabl success gastric cancer probabl
success assign valu probability-weight opportun baumannii
probabl success earlier stage develop program repres potenti sourc long-
term upsid valuat use discount rate termin growth rate
zlab pipelin program face clinic regulatori develop risk well commerci
intellectu properti risk zlab also face execut risk financi risk zlab may
addit financ need turn cash flow posit
zlab mm except per share
product sale minu royalti lessor p/w
licens collabor revenu
chang fair valu warrant
net incom tax
share loss equiti method invest
zlab bs cf mm
sec file svb leerink estim
chang
effect exchang rate cash
sec file svb leerink estim
approv hong kong hong kong launch
zlab pipelin upcom event
approv mainland
china snda submit nda submit base result prima studi
approv us eu
approv us eu
initi registr bridg trial late line ovarian
china launch follow gbm nda approv
mesothelioma stellar trial concomit pemetrex cisplatin
concomit sorafenib hepanova
nsclc lunar trial concurr standard therapi
pancreat panova trial concomit gemcitabin nab-
small molecul inhibitor kit
pdgfr
line breast cancer
initi bridg trial gist
final os data phase sophia studi
gastric cancer combin niraparib
phase data scientif confer
on-going first patient dose feb
gastric gej cancer mahogani combin anti-
bispecif chemotherapi
multipl monotherapi combin studi across oncolog
initi data registration-direct studi msi-high
endometri anal merkel cell carcinoma
gastric gastro-esophag junction cancer phase i/iii fight studi
cabp context coronaviru infect
nmpa prioriti review submit februari
tnbc china
brca china
nsclc brain met meti
